Less than a year ago, Thorasys, a Montreal-based SME, launched the Tremoflo C2, a new generation of portable oscillometry device used to detect respiratory problems. The company dedicated nearly seven years to its development with the goal of making this technology more accessible to physicians.
Published yesterday at 13:00, Julie Roy, a collaboration journalist, reported on how the Tremoflo helps detect respiratory issues such as asthma, emphysema, and chronic bronchitis, offering a less physically demanding alternative to traditional spirometry tests.
Thorasys President, Yvan Beaudoin, described Tremoflo as a radar-like device that examines the lungs in depth, identifying obstructions in the airways through unique oscillations and mathematical calculations.
Although the measurement technique has been around since the 1950s, Thorasys successfully democratized it with the Tremoflo.
The latest version of Tremoflo, the C2, is smaller, portable, and equipped with Bluetooth connectivity for quick and easy results interpretation. Thorasys focused on making it affordable and compatible with other pulmonary devices, aiming to enhance ease of use.
Thorasys had already sold its previous version, Tremoflo C100, in over 25 countries. However, launching the C2 required revalidating certifications, updating software, and addressing language support challenges.
Yvan Beaudoin emphasized the importance of rapid detection of lung diseases and the long process involved in bringing medical devices to market.
Thorasys aims to sell over 50,000 units of Tremoflo annually, with expanded production facilities and global hiring to enhance customer service.
The company is now looking towards integrating artificial intelligence (AI) into their device for their next version, recognizing the significant potential of data processing in the future of respiratory health monitoring.
